Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy
treatment of patients newly diagnosed with operable breast cancer.
Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the
tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of
this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side
effect profile with the addition of Herceptin, and 4) evaluate significance of HER2
expression by two different methods.